NEOADJUVANT TARGET THERAPY IN A RENAL-CELL CANCER
There were observed 30 patients (32 tumors), to whom preoperatively for renal-cell cancer (ROC) a neoadjuvant target therapy (NATTH) was conducted. In 19 (66.7%) of them a pazopanib (800 mg per os once a day through 2 mo) was applied, and in 10 (33.3%)--sunitinib (50 mg per os once a day through 28 days, the gap--14 days, repeated course--28 days). The indications for the NATTH conduction were: in 7 (21.9%) patients--a locally--spread RCC with the objective to localize a tumor and to search a further possibility of radical surgical intervention performance, and in 25 (78.1%)--the tumor reduction and searching possibility of the organpreserving treatment conduction. The NATTH conduction in the patients, suffering RCC, have guaranteed a primary pathological focus reduction in 90% of observations, and a partial regression in accordance to the RECIST criteria--in 28.1%. A tumor reduction by (22.9 ± 17.8)% at average have permitted to perform a renal resection in 75% of observations, concerning localized RCC, when indication of preservation of enough functioning renal parenchyma was secured.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2015 |
|---|---|
| Erschienen: |
2015 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2015 |
|---|---|
| Enthalten in: |
Klinichna khirurhiia - (2015), 12 vom: Dez., Seite 41-3 |
| Sprache: |
Ukrainisch |
|---|
| Beteiligte Personen: |
Stakhovskiy, E O [VerfasserIn] |
|---|
| Themen: |
7RN5DR86CK |
|---|
| Anmerkungen: |
Date Completed 08.04.2016 Date Revised 03.12.2021 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM258886633 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM258886633 | ||
| 003 | DE-627 | ||
| 005 | 20231224190005.0 | ||
| 007 | tu | ||
| 008 | 231224s2015 xx ||||| 00| ||ukr c | ||
| 028 | 5 | 2 | |a pubmed24n0863.xml |
| 035 | |a (DE-627)NLM258886633 | ||
| 035 | |a (NLM)27025031 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a ukr | ||
| 100 | 1 | |a Stakhovskiy, E O |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a NEOADJUVANT TARGET THERAPY IN A RENAL-CELL CANCER |
| 264 | 1 | |c 2015 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 08.04.2016 | ||
| 500 | |a Date Revised 03.12.2021 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a There were observed 30 patients (32 tumors), to whom preoperatively for renal-cell cancer (ROC) a neoadjuvant target therapy (NATTH) was conducted. In 19 (66.7%) of them a pazopanib (800 mg per os once a day through 2 mo) was applied, and in 10 (33.3%)--sunitinib (50 mg per os once a day through 28 days, the gap--14 days, repeated course--28 days). The indications for the NATTH conduction were: in 7 (21.9%) patients--a locally--spread RCC with the objective to localize a tumor and to search a further possibility of radical surgical intervention performance, and in 25 (78.1%)--the tumor reduction and searching possibility of the organpreserving treatment conduction. The NATTH conduction in the patients, suffering RCC, have guaranteed a primary pathological focus reduction in 90% of observations, and a partial regression in accordance to the RECIST criteria--in 28.1%. A tumor reduction by (22.9 ± 17.8)% at average have permitted to perform a renal resection in 75% of observations, concerning localized RCC, when indication of preservation of enough functioning renal parenchyma was secured | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 650 | 7 | |a Indazoles |2 NLM | |
| 650 | 7 | |a Indoles |2 NLM | |
| 650 | 7 | |a Pyrimidines |2 NLM | |
| 650 | 7 | |a Pyrroles |2 NLM | |
| 650 | 7 | |a Sulfonamides |2 NLM | |
| 650 | 7 | |a pazopanib |2 NLM | |
| 650 | 7 | |a 7RN5DR86CK |2 NLM | |
| 650 | 7 | |a Sunitinib |2 NLM | |
| 650 | 7 | |a V99T50803M |2 NLM | |
| 700 | 1 | |a Voylenko, O A |e verfasserin |4 aut | |
| 700 | 1 | |a Stakhovskiy, O E |e verfasserin |4 aut | |
| 700 | 1 | |a Vitruk, Yu V |e verfasserin |4 aut | |
| 700 | 1 | |a Vukalovych, P S |e verfasserin |4 aut | |
| 700 | 1 | |a Kononenko, O A |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Klinichna khirurhiia |d 1993 |g (2015), 12 vom: Dez., Seite 41-3 |w (DE-627)NLM085989835 |x 0023-2130 |7 nnns |
| 773 | 1 | 8 | |g year:2015 |g number:12 |g month:12 |g pages:41-3 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2015 |e 12 |c 12 |h 41-3 | ||